Improvement in facial\/total Vitiligo Area Scoring Index seen with continued treatment from weeks 52 to 104<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, March 28, 2023 (HealthDay News) — For patients with nonsegmental vitiligo, continued improvement was seen during a long-term extension of ruxolitinib treatment, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 17 to 21 in New Orleans.<\/p>\n
Noting that ruxolitinib cream demonstrated facial and total body repigmentation over 52 weeks in two phase 3 vitiligo studies (TRuE-V1\/TRuE-V2), David Rosmarin, M.D., from the Indiana University School of Medicine in Indianapolis, and colleagues examined shifts in facial\/total Vitiligo Area Scoring Index (F-VASI\/T-VASI) responses during an additional 52 weeks of open-label ruxolitinib treatment among patients aged 12 years and older who did not achieve \u00e2\u0089\u00a590 percent improvement in F-VASI (F-VASI90) at week 52.<\/p>\n
The researchers found that 66.1 percent of the 222 patients initially randomly assigned to ruxolitinib achieved F-VASI75 at week 104, up from 30.8 percent at week 52 and 54.6 percent at week 80; a corresponding increase in T-VASI50 was seen, from 42.5 and 57.7 to 63.8 percent. At week 104, 30.9 percent attained F-VASI90. At week 80, 36.2 and 47.1 percent, respectively, remained stable and had improvement in F-VASI responses attained at week 52; 51.1 and 31.7 percent, respectively, remained stable and had improvement in T-VASI responses attained at week 52. Compared with results attained at week 80, at week 104, 64.4 and 19.6 percent, respectively, remained stable and had improvement in F-VASI responses, while 61.3 and 22.2 percent, respectively, remained stable and had improvement in T-VASI responses.<\/p>\n
“Vitiligo is a chronic condition and these results demonstrate the long-term potential of this medical treatment for people with vitiligo who are interested in repigmentation,” Rosmarin said in a statement.<\/p>\n
Several authors disclosed financial ties to pharmaceutical companies, including Incyte, which manufactures ruxolitinib and sponsored the study.<\/p>\n
Poster Presentation<\/a><\/p>\n